These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2064323)

  • 1. New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA.
    Jehn U; Heinemann V
    Anticancer Res; 1991; 11(2):705-11. PubMed ID: 2064323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New drugs in the treatment of acute and chronic leukaemia: current role of mAMSA.
    Jehn U
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():53-8. PubMed ID: 2697402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
    Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
    Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acridinyl anisidide (m-AMSA) therapy in 11 patients with refractory acute leukemia.
    Naparstek E; Shinar E; Polliack A
    Isr J Med Sci; 1984 Feb; 20(2):118-22. PubMed ID: 6546740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMSA--a promising new agent in refractory acute leukemia.
    Lawrence HJ; Ries CA; Reynolds RD; Lewis JP; Koretz MM; Torti FM
    Cancer Treat Rep; 1982 Jul; 66(7):1475-8. PubMed ID: 7046928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
    Ogawa M
    Gan To Kagaku Ryoho; 1986 May; 13(5):1829-36. PubMed ID: 3754711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. m-AMSA: phase II trial in advanced lymphoma and leukemia.
    Case DC
    Am J Clin Oncol; 1984 Aug; 7(4):357-60. PubMed ID: 6588746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phase II clinical trial of domestic amsacrine in patients with acute leukemias. Cooperative Group for Treating Acute Leukemias with Domestic m-AMSA].
    Zhonghua Nei Ke Za Zhi; 1993 Feb; 32(2):80-4. PubMed ID: 8404329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase II as a target of antileukemic drugs.
    Zwelling LA; Estey E; Bakic M; Silberman L; Chan D
    NCI Monogr; 1987; (4):79-82. PubMed ID: 2819736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
    Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
    Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992) in children with acute leukemia and lymphoma.
    Tan CT; Hancock C; Steinherz PG; Steinherz LJ; Sorell M; Chan KW; Mondora A; Miller DR
    Cancer Res; 1982 Apr; 42(4):1579-81. PubMed ID: 6895864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).
    Fanucchi MP; Arlin ZA
    Cancer Chemother Pharmacol; 1982 Dec; 10(1):27-8. PubMed ID: 6961970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amsacrine (m-AMSA): a new antineoplastic agent. Pharmacology, clinical activity and toxicity.
    Hornedo J; Van Echo DA
    Pharmacotherapy; 1985; 5(2):78-90. PubMed ID: 2582401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
    Bakic M; Chan D; Freireich EJ; Marton LJ; Zwelling LA
    Cancer Res; 1987 Dec; 47(24 Pt 1):6437-43. PubMed ID: 2824033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
    Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chronic leukemia].
    Shibata A; Narita M
    Gan To Kagaku Ryoho; 1989 May; 16(5):1982-8. PubMed ID: 2658837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.
    Cassileth PA; Lyman GH; Bennett JM; Glick JH; Oken MM
    Am J Clin Oncol; 1984 Aug; 7(4):361-3. PubMed ID: 6547566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL).
    Carella AM; Santini G; Martinengo M; Nati S; Giordano D; Congiu A; Cerri R; Damasio E; Risso M; Rossi E
    Haematologica; 1985; 70(1):39-43. PubMed ID: 2408974
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.